Introduction:
Leading pharma company has received final USFDA approval for its generic version of Paclitaxel Protein-bound Particles, used in treating metastatic breast cancer, NSCLC, and pancreatic cancer, with launch expected in H1 FY 2025-26.
Also Read: Railway Stock: Oriental Rail Infra secures order worth ₹3.99 Cr from Rail Coach Factory
Share price movement of Cipla:
On April 11, 2025, Cipla Ltd opened at ₹1,465.30, up 3.46% from its previous close of ₹1,416.30. The stock hit a high of ₹1,488.80 and a low of ₹1455.00. By 9:59 AM, it traded at ₹1,469.90, marking a 3.78% gain, with a market cap of ₹1,18,711.64 crore.
Cipla Gets USFDA Nod for Oncology Drug:
Cipla Limited has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial, on April 10, 2025.
The approved product is an AB-rated generic equivalent of Bristol Myers Squibb’s Abraxane®, indicated for treating metastatic breast cancer, NSCLC, and pancreatic adenocarcinoma. Cipla plans to launch the drug in the U.S. during the first half of FY 2025-26.
Recent news on Cipla:
As of March 18, 2025, Cipla Ltd entered an exclusive licensing agreement with Formosa Pharmaceuticals to market clobetasol propionate ophthalmic suspension across 11 countries for post-operative ocular inflammation and pain.
Stock performance of Cipla for Period of 1 week, 6 months, and 1 year:
Cipla Ltd delivered a 0.02% return over the past week. It declined by 11.3% in the past six months, while the stock saw a marginal dip of 0.52% over the past year.
Also Read: Navratna PSU stock to watch after it signs MoU with DP World
Shareholding pattern of Cipla:
| Particulars | Dec 2024 | Sep 2024 | Jun 2024 |
| Promoter | 29.20% | 30.90% | 30.90% |
| FII | 27% | 29% | 28% |
| DII | 27.70% | 24.20% | 24.90% |
| Public | 16.40% | 16.10% | 16.30% |
About Cipla:
Cipla Ltd (NSE: CIPLA) is a leading global pharmaceutical company focused on affordable and innovative medicines. It operates across key therapeutic areas, including respiratory, oncology, and cardiovascular, with a strong presence in over 80 countries worldwide.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
